SP 0237
Alternative Names: Influenza virus vaccine quadrivalent - Sanofi; MRT-5421; MRT-5424; MRT-5429; Quadrivalent messenger RNA influenza vaccine - Sanofi; SP-0237Latest Information Update: 22 Jun 2024
At a glance
- Originator Sanofi
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 01 Apr 2024 Phase-I/II clinical trials in Influenza virus infections (Prevention) in Puerto Rico (IM) (NCT06361875)
- 01 Apr 2024 Phase-I/II clinical trials in Influenza virus infections (Prevention) in USA (IM) (NCT06361875)